CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 327 enrolled
Drug / intervention
Intravenous magnesium sulfate infusiondrug
Likely dose
Intravenous magnesium sulfate infusion 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00124150
NCT00124150Phase 3Completed
CompareCT.gov

Phase 3 Study (Multi-center, Randomized Controlled Clinical Trial) of Intravenous Magnesium Sulfate to Improve Outcome After Aneurysmal Subarachnoid Haemorrhage

Chinese University of Hong Kong·interventional·Posted Jul 27, 2005·Updated Dec 23, 2009

In Brief

A Phase 3 clinical trial evaluating Intravenous magnesium sulfate infusion for Subarachnoid Hemorrhage. Completed, enrolled 327 participants across 1 site.

Detailed Summary

The IMASH trial is a simple, randomized, double-blinded, placebo-controlled, multi-center trial to answer the question: "Does intravenous magnesium sulfate improve clinical outcome after aneurysmal subarachnoid hemorrhage?"

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubarachnoid Hemorrhage
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 27, 2005
Enrollment StartJun 1, 2002
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 20.9 years ago

Interventions

Intravenous magnesium sulfate infusiondrug

80mg per day